Menu
Search
|

Menu

Close
X

Citius Pharmaceuticals Inc CTXR.OQ (NASDAQ Stock Exchange Capital Market)

1.02 USD
-- (--)
As of Jul 18
Previous Close 1.02
Open --
Volume --
3m Avg Volume 25,940
Today’s High --
Today’s Low --
52 Week High 3.14
52 Week Low 0.86
Shares Outstanding (mil) 22.08
Market Capitalization (mil) 22.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.415
FY18
-1.218
FY17
-1.931
FY16
-2.159
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.10
Price to Sales (TTM)
vs sector
--
7.99
Price to Book (MRQ)
vs sector
0.92
4.39
Price to Cash Flow (TTM)
vs sector
--
24.00
Total Debt to Equity (MRQ)
vs sector
0.83
17.94
LT Debt to Equity (MRQ)
vs sector
0.00
12.82
Return on Investment (TTM)
vs sector
-55.78
12.64
Return on Equity (TTM)
vs sector
-55.78
17.18

EXECUTIVE LEADERSHIP

Leonard Mazur
Executive Chairman of the Board, Secretary, Since 2016
Salary: $250,000.00
Bonus: $120,000.00
Myron Holubiak
President, Chief Executive Officer, Director, Since 2016
Salary: $225,000.00
Bonus: $112,500.00
Jaime Bartushak
Chief Financial Officer, Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Suren Dutia
Director, Since 2015
Salary: --
Bonus: --
Eugene Holuka
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11 Commerce Dr Fl 1
CRANFORD   NJ   07016-3501

Phone: +1908.9676677

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

SPONSORED STORIES